RRML - Acute myeloid leukemia treatment – between therapeutic benefit and iatrogenic pathology

RRML - Acute myeloid leukemia treatment – between therapeutic benefit and iatrogenic pathology – case report

Main page
News
RJLabM Credits
Archive
- Current issue
- Ahead of print
- List of published issues
- 2023
  - Nr.1/2023
- 2022
  - Nr.4/2022
  - Nr.3/2022
  - Nr.2/2022
  - Nr.1/2022
  - Supplement 1/2022
- 2021
  - Nr.4/2021
  - Nr.3/2021
  - Nr.2/2021
  - Nr.1/2021
- 2020
  - Nr.4/2020
  - Nr.3/2020
  - Nr.2/2020
  - Nr.1/2020
  - Supplement 1/2020
- 2019
  - Nr.4/2019
  - Nr.3/2019
  - Nr.2/2019
  - Nr.1/2019
  - Supplement 1/2019
- 2018
  - Nr.4/2018
  - Nr.3/2018
  - Nr.2/2018
  - Nr.1/2018
  - Supplement 1/2018
  - Supplement 2/2018
  - Supplement 3/2018
- 2017
  - Nr.4/2017
  - Nr.3/2017
  - Nr.2/2017
  - Nr.1/2017
  - Supplement 1/2017
- 2016
  - Nr.4/2016
  - Nr.3/2016
  - Nr.2/2016
  - Nr.1/2016
  - Supplement 1/2016
- 2015
  - Nr.4/2015
  - Nr.3/2015
  - Nr.2/2015
  - Nr.1/2015
  - Supplement 1/2015
- 2014
  - Nr.4/2014
  - Nr.3/2014
  - Nr.2/2014
  - Nr.1/2014
  - Supplement 1/2014
- 2013
  - Nr.4/2013
  - Nr.3/2013
  - Nr.2/2013
  - Nr.1/2013
  - Supplement 1/2013
- 2012
  - Nr.4/2012
  - Nr.3/2012
  - Nr.2/2012
  - Nr.1/2012
  - Supplement 1/2012
- 2011
  - Nr.4/2011
  - Nr.3/2011
  - Nr.2/2011
  - Nr.1/2011
  - Supplement 1/2011
- 2010
  - Nr.4/2010
  - Nr.3/2010
  - Nr.2/2010
  - Nr.1/2010
  - Supplement 1/2010
- 2009
  - Nr.4/2009
  - Nr.3/2009
  - Nr.2/2009
  - Nr.1/2009
  - Supplement 1/2009
- 2008
  - Nr.4/2008
  - Nr.3/2008
  - Nr.2/2008
  - Nr.1/2008
  - Supplement 1/2008
- 2007
  - Nr.4/2007
  - Nr.3/2007
  - Nr.2/2007
  - Nr.1/2007
- 2006
  - Nr.4/2006
  - Nr.3/2006
  - Nr.2/2006
  - Nr.1/2006
- 2005
  - Nr.1/2005
Instructions for authors
Online applications
- Send an article
- Online payments
Editorial
About us
Links

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Journal Metrics

Impact Factor 0.493
Five Year Impact Factor 0.531
SNIP 0.373
JCI 0.17

Top 10 downloaded articles - March 2023 -

Making the most out of profici...	19
Romanian Review of Laboratory ...	10
Vitamin K and bone metabolism...	9
Endothelial progenitor cell (E...	8
The Role of procollagen type 1...	8
Non-invasive markers of fibros...	6
Expressions and clinical signi...	6
Approaching Risk Management in...	6
Phenotypic Carbapenemase Produ...	6
Association of HLA class II al...	6

Concept, Design & Programming
Dr. Adrian Man

Nr. 10(1)/2008

Acute myeloid leukemia treatment – between therapeutic benefit and iatrogenic pathology – case report

Anca Bacârea, Bogdana Dorcioman, Minodora Dobreanu, Galafteon Oltean, Smaranda Demian, Anamaria Rusu, Maria T. Dogaru, Camil Eugen Vari

Abstract:

The treatment of acute myeloid leukemia specific includes antracyclinic compounds and cytrabine; the limitation factor of clinical efficacy is dose-related drug toxicity. Beside cytotoxic specific adverse reactions, the claimed medication presents a target cardiac toxicity. This paper presents a clinical case, the relationship between medication and iatrogenic risks and also patient prognosis.

Keywords: acute myeloid leukemia,treatment,prognostic

Download full text PDF
(917 KB)

Bacârea A, Dorcioman B, Dobreanu M, Oltean G, Demian S, Rusu A, et al. Acute myeloid leukemia treatment – between therapeutic benefit and iatrogenic pathology – case report. Rev Romana Med Lab. 2008;10(1):33-8